PEOPLE - Aprogenex (US) announces the first in a series of management changes:
This article was originally published in Clinica
Aprogenex (US) has announced the first in a series of management changes during its transition from a development- stage to commercial operations company. An executive committee of three has been formed. For an initial period, the company's founder, Dr Joel Bresser will serve as one of these, having resigned as president & CEO. The remaining two are Walter Cunningham and Terry Ward, both experienced venture capital executives. A search has been initiated for a new CEO and Dr Luis Cantarero has been named acting COO, having been vice-president of R&D since 1994. In addition, Dr Wayne Ryan and Donald Payne have joined the Aprogenex board, replacing Dr Irvin Smith and John Davis.
You may also be interested in...
Will the second wave of coronavirus lockdown have the same impact on the European consumer health industry? Speaking exclusively to HBW Insight from Germany, Merz Consumer Care CEO Frank Baldauf thinks not. Recently investing in premium beard care brand Brooklyn Soap and launching its tetesept Formula range in the Netherlands, Merz's Baldauf suggest that there will be less panic buying this time round and the CHC supply chain will hold up under pressure.
After a strong first quarter, Japan’s Towa Pharmaceuticals saw stability in its domestic revenues but a drop in revenues from its overseas business in its financial second quarter. After launching a series of molecules in June 2020, the company has lined up 10 launches for December 2020 as well.
Pfizer has revealed launch plans for its Nyvepria pegfilgrastim biosimilar, shortly after receiving formal European Commission approval.